NCT03471130View on ClinicalTrials.gov

Definitive QT Study With MT-8554

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 23, 2018

Primary Completion Date

October 19, 2018

Study Completion Date

October 19, 2018

Conditions
Healthy Volunteer
Interventions
DRUG

MT-8554 Low dose

Oral, 7 days

DRUG

MT-8554 High dose

Oral, 7 days

DRUG

Placebo

Oral, 7 days

Trial Locations (1)

Unknown

Investigational center, City Name

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma America Inc.

INDUSTRY